Last updated: 2026-10-19 23:00:01. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Corvus Pharmaceuticals, Inc. (CRVS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.65, with a market capitalization of $800.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.39 to $26.95. This page covers its latest market performance, valuation, price trends and company information.
$800.83M | |
$9.73 | |
$26.95 | |
$0.61 | |
$9.52 | |
652.56K | |
982.18K | |
-- | |
$26.95 | |
$6.39 | |
-- | |
-- |
Corvus Pharmaceuticals, Inc. (CRVS) is trading at $9.79 in after-hours trading as of 2026-10-19 22:16:00, up 2.78% ($0.27) from the regular-session close of $9.52.
After-hours trading shows how investors are pricing CRVS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Corvus Pharmaceuticals, Inc. (CRVS) moved from $10.21 to $9.65, representing a decline of 5.48% ($0.56).
The stock traded between $9.21 and $10.71 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.19 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 15.9%
CRVS is currently trading at $9.65, placing it 15.9% of the way from its 52-week low of $6.39 to its 52-week high of $26.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 37 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Corvus Pharmaceuticals, Inc. (CRVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.